SCHEMBL22291111

SCHEMBL22291111

COc1cc(-c2nc(C(C)C)c(C(C)C)[nH]2)cc(OC)c1OS(C)(=O)=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMPD3 Q9NY59 4/20 0.64
CDK4 P11802 1/20 0.40
CCND1 P24385 1/20 0.40
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
MPI P34949 1/20 0.35
APOBEC3G Q9HC16 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
POLB P06746 1/20 0.35
TSHR P16473 1/20 0.35
PARP1 P09874 3/20 0.34
PARP2 Q9UGN5 2/20 0.33
CDKN1A P38936 3/20 0.33
BRD4 O60885 1/20 0.33
SLC9A1 P19634 1/20 0.33
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22291107 0.79 SMPD3 (1.00) SMPD3TP53MAPT
SCHEMBL22301855 0.72 CDK4 (0.56) CDK4CCND1KDM4EALDH1A1GAA
SCHEMBL22301893 0.72 CDK4 (0.42) SMPD3CDK4CCND1GAAPARP1
SCHEMBL29580411 0.67 ALDH1A1 (0.58) SMPD3CDK4CCND1KDM4EALDH1A1
SCHEMBL22301854 0.65 CDK4 (0.31) CDK4CCND1
SCHEMBL2456957 0.65 CYP1A2 (0.46) PDE3BPDE3AALDH1A1
SCHEMBL14421949 0.65 ACHE (0.58) ALDH1A1TSHR
SCHEMBL13605207 0.64 SMPD3 (0.53) SMPD3KDM4EALDH1A1GAAPOLB
SCHEMBL29580655 0.63 TSHR (0.43) SMPD3CDK4CCND1KDM4EALDH1A1
SCHEMBL22291073 0.61 ALDH1A1 (0.51) KDM4EALDH1A1GAATDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220119374-A1 SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (nSMase2) INHIBITORS THE JOHNS HOPKINS UNIVERSITY 2022-04-21 US disclosed
EP-3917530-A1 SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (NSMASE2) INHIBITORS The Johns Hopkins University (US) 2021-12-08 EP disclosed
WO-2020160148-A1 SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (NSMASE2) INHIBITORS THE JOHNS HOPKINS UNIVERSITY (US) 2020-08-06 WO disclosed
WO-2020160148-A1 SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (NSMASE2) INHIBITORS THE JOHNS HOPKINS UNIVERSITY (US) 2020-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119374-A1 SMALL MOLECULE NEUTRAL SPHINGOMYELINASE 2 (nSMase2) INHIBITORS SMPD2, SPTLC2, SGMS2 SMPD3 8/4885CDK4 3727/4885CCND1 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.